Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Richaud

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trialPaul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
Environmental Microbiology|May 14, 2013
Soil metatranscriptomics for mining eukaryotic heavy metal resistance genesFrédéric Lehembre, Didier Doillon, Elise David, et al.
Plos One|January 5, 2012
Heterologous expression of membrane proteins: choosing the appropriate hostFlorent Bernaudat, Annie Frelet-Barrand, Nathalie Pochon, et al.
Lancet (London, England)|October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataClaire L Vale, David Fisher, Andrew Kneebone, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
Critical role of Chlamydomonas reinhardtii ferredoxin-5 in maintaining membrane structure and dark metabolismWenqiang Yang, Tyler M Wittkopp, Xiaobo Li, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trialPaul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
Environmental Microbiology|May 14, 2013
Soil metatranscriptomics for mining eukaryotic heavy metal resistance genesFrédéric Lehembre, Didier Doillon, Elise David, et al.
Plos One|January 5, 2012
Heterologous expression of membrane proteins: choosing the appropriate hostFlorent Bernaudat, Annie Frelet-Barrand, Nathalie Pochon, et al.
Lancet (London, England)|October 1, 2020
Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate dataClaire L Vale, David Fisher, Andrew Kneebone, et al.
The Lancet. Oncology|May 11, 2016
Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trialChristian Carrie, Ali Hasbini, Guy de Laroche, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2015
Critical role of Chlamydomonas reinhardtii ferredoxin-5 in maintaining membrane structure and dark metabolismWenqiang Yang, Tyler M Wittkopp, Xiaobo Li, et al.
Pageof 8